Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Tamura

Showing results (1231-1240 of 1,263) with videos related to

Pageof 127
Sort By:
Japanese Journal of Clinical Oncology|March 21, 2002
A phase I/II study of cisplatin and vinorelbine chemotherapy in patients with advanced non-small cell lung cancerK Hotta, I Sekine, T Tamura, et al.
British Journal of Cancer|March 20, 2003
Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507I Sekine, Y Nishiwaki, R Kakinuma, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 4, 2001
[Comparison of management of advanced cancer in various organs]H Akaza, T Saeki, K Kawai, et al.
Gastrointestinal Endoscopy|May 27, 1999
Interobserver and intraobserver variation in endoscopic assessment of GERD using the "Los Angeles" classificationM Kusano, K Ino, T Yamada, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancerF Oshita, K Noda, Y Nishiwaki, et al.
British Journal of Cancer|January 1, 1997
Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancerM Ando, K Eguchi, T Shinkai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2015
Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)K Takeuchi, Y Togashi, Y Kamihara, et al.
Bone Marrow Transplantation|May 13, 1998
Diagnostic value of hemostatic parameters in bone marrow transplant-associated thrombotic microangiopathyH Kanamori, A Maruta, S Sasaki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2015
A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)H Yoshioka, K Azuma, N Yamamoto, et al.
British Journal of Cancer|July 29, 2004
Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancerK Goto, I Sekine, Y Nishiwaki, et al.
Pageof 127

Showing results (1231-1240 of 1,263) with videos related to

Sort By:
Pageof 127
Japanese Journal of Clinical Oncology|March 21, 2002
A phase I/II study of cisplatin and vinorelbine chemotherapy in patients with advanced non-small cell lung cancerK Hotta, I Sekine, T Tamura, et al.
British Journal of Cancer|March 20, 2003
Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507I Sekine, Y Nishiwaki, R Kakinuma, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 4, 2001
[Comparison of management of advanced cancer in various organs]H Akaza, T Saeki, K Kawai, et al.
Gastrointestinal Endoscopy|May 27, 1999
Interobserver and intraobserver variation in endoscopic assessment of GERD using the "Los Angeles" classificationM Kusano, K Ino, T Yamada, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancerF Oshita, K Noda, Y Nishiwaki, et al.
British Journal of Cancer|January 1, 1997
Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancerM Ando, K Eguchi, T Shinkai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2015
Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)K Takeuchi, Y Togashi, Y Kamihara, et al.
Bone Marrow Transplantation|May 13, 1998
Diagnostic value of hemostatic parameters in bone marrow transplant-associated thrombotic microangiopathyH Kanamori, A Maruta, S Sasaki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2015
A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)H Yoshioka, K Azuma, N Yamamoto, et al.
British Journal of Cancer|July 29, 2004
Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancerK Goto, I Sekine, Y Nishiwaki, et al.
Pageof 127